ArticleBioconjugate chemistry2008
Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier.
Article in Bioconjugate chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Silencing with precision: In silico strategies for antisense oligonucleotide engineering.Molecular biology reports · 2026Review
- Targeting ZC3H11A elicits immunogenic cancer cell death through augmentation of antigen presentation and interferon response.Molecular therapy. Nucleic acids · 2024Article
- Albumin Nanostructures for Nucleic Acid Delivery in Cancer: Current Trend, Emerging Issues, and Possible Solutions.Cancers · 2021Review
- Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers.Frontiers in chemistry · 2021Review
- Phosphorothioate modified oligonucleotide-protein interactions.Nucleic acids research · 2020Article
- Efficient bioactive oligonucleotide-protein conjugation for cell-targeted cancer therapy.ChemistryOpen · 2019Article
- The delivery of therapeutic oligonucleotides.Nucleic acids research · 2016Review
- Bioconjugates for targeted delivery of therapeutic oligonucleotides.Advanced drug delivery reviews · 2015Review
- Targeted albumin-based nanoparticles for delivery of amphipathic drugs.Bioconjugate chemistry · 2011Article
- Integrin targeted delivery of gene therapeutics.Theranostics · 2011Article
- The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking.Oligonucleotides · 2010Article
- Biological barriers to therapy with antisense and siRNA oligonucleotides.Molecular pharmaceuticsReview
- Efficient delivery of antisense oligodeoxyribonucleotide g3139 by human serum albumin-coated liposomes.Molecular pharmaceuticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Targeted delivery can potentially improve the pharmacological effects of antisense and siRNA oligonucleotides. Here, we describe a novel bioconjugation approach to the delivery of splice-shifting antisense oligonucleotides (SSOs). The SSOs are linked to albumin via reversible S-S bonds. The albumin is also conjugated with poly(ethylene glycol) (PEG) chains that terminate in an RGD ligand that selectively binds the alphavbeta3 integrin. As a test system, we utilized human melanoma cells that express the alphavbeta3 integrin and that also contain a luciferase reporter gene that can be induced by delivery of SSOs to the cell nucleus. The RGD-PEG-SSO-albumin conjugates were endocytosed by the cells in an RGD-dependent manner; using confocal fluorescence microscopy, evidence was obtained that the SSOs accumulate in the nucleus. The conjugates were able to robustly induce luciferase expression at concentrations in the 25-200 nM range. At these levels, little short-term or long-term toxicity was observed. Thus, the RGD-PEG-albumin conjugates may provide an effective tool for targeted delivery of oligonucleotides to certain cells and tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.